Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long-term, multi-institutional study. The study ...

The use of active surveillance or watchful waiting increased by more than twofold overall between 2010 and 2020 among patients with intermediate-risk prostate cancer. Current guidelines support active ...

In focused radiotherapy for prostate cancer (PC), a full dose of radiation is delivered to the index lesion while reduced dose is delivered to the remaining prostate to reduce morbidity. As PC is ...

Adding external-beam radiation to brachytherapy does not improve 5-year freedom from progression (FFP) for men with intermediate-risk prostate cancer, but it does increase treatment toxicity. The ...

Survival curves separated as early as 4 to 5 years after initiation of active surveillance or active treatment, investigators reported. Active surveillance (AS) should be cautiously offered to men ...

SBRT is noninferior to traditional radiation for low- to intermediate-risk localized prostate cancer, offering a viable treatment alternative. The PACE-B study showed a 95.8% five-year rate of no ...

The rate of active surveillance as initial treatment increased from 2.0% in 2010 to 8.6% in 2020. The use of active surveillance in patients with intermediate-risk prostate cancer has increased in ...

Two-year PSA outcomes after cesium prostate brachytherapy. Background: A wide range of therapeutic alternatives is available for the treatment of intermediate-risk prostate cancer (IRPC). The use of ...

Researchers have characterized prostate cancer cell dynamics at a single-cell resolution across the timespan of the disease – from its beginning to the point of androgen independence, where the tumour ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), ...